Transdermal clonidine for smoking cessation: A double-blind randomized dose–response study. |
| |
| Authors: | Niaura, Raymond Brown, Richard A. Goldstein, Michael G. Murphy, Joseph K. Abrams, David B. |
| |
| Abstract: | A 4-week trial tested the effects of 4 doses (placebo, 0.1 mg/d, 0.2 mg/d, and 0.3 mg/d) of transdermal clonidine on smoking cessation and nicotine withdrawal. After a 1-week baseline, smokers (N?=?72) started the drug and tried to quit by Week 3. Significantly fewer smokers who received a placebo were abstinent at 5 days after quitting as compared with smokers who received clonidine at any dose (19% vs 57%, respectively, p?=?.007). Blood clonidine concentration interacted with nicotine dependence (p? |
| |
| Keywords: | |
|
|
